Found: 4
Select item for more details and to access through your institution.
Cancerous inhibitor of protein phosphatase 2A (CIP2A) modifies energy metabolism via 5' AMP-activated protein kinase signalling in malignant cells.
- Published in:
- Biochemical Journal, 2019, v. 476, n. 15, p. 2255, doi. 10.1042/BCJ20190121
- By:
- Publication type:
- Article
Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia.
- Published in:
- Cancers, 2021, v. 13, n. 9, p. 2155, doi. 10.3390/cancers13092155
- By:
- Publication type:
- Article
Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".
- Published in:
- Science Translational Medicine, 2019, v. 11, n. 501, p. 1, doi. 10.1126/scitranslmed.aau0416
- By:
- Publication type:
- Article
BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia.
- Published in:
- 2010
- By:
- Publication type:
- Letter